Skip to content
2000
Volume 30, Issue 29
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Introduction: Esophageal-squamous Cell Carcinoma (ESCC) is often diagnosed at the middle or late stage, thus requiring more effective therapeutic strategies. Pharmacologically, the anti-tumor activity of the principal active constituent of , matrine (MA), has been explored widely. Notwithstanding, it is significant to nanotechnologically enhance the anti-tumor activity of MA in view of its potential to distribute non-tumor cells. Methods: Herein, MA-loaded Nano-Liposomes (MNLs) were prepared to enhance the effect of anti-ESCC. The MNL showed a smaller sized particle (25.95 ± 1.02 nm) with a low polydispersed index (PDI = 0.130 ± 0.054), uniform spherical morphology, good solution stability, and encapsulated efficiency (65.55% ± 2.47). Furthermore, we determined the characteristics of KYSE-150 cells by cell viability assay, IC, Mitochondrial Membrane Potential (MMP), Western blot, and apoptotic analysis, which indicated that MNLs down-regulated the cell viability and IC in a concentration-dependent manner and induced a significant change in JC-1 fluorescence from red to green. Results: The above observations resulted in increased Bax and Caspase-3 levels, coupled with a substantial decrease in Bcl-2 and apoptotic promotion at the advanced stage compared with MA. Conclusion: Based on these results, MNLs may serve as a more effective and promising therapeutic option for ESCC.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128306477240625101849
2024-08-01
2025-04-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/0113816128306477240625101849
Loading

  • Article Type:
    Research Article
Keyword(s): apoptosis; esophageal-squamous; KYSE-150; Matrine; nano-liposome; nanoliposome
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test